HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NSC 659687

Also Known As:

9-hydroxy-5,6-dimethyl-1-(N-(2(dimethylamino)ethyl)carbamoyl)-6H-pyrido-(4,3-b)carbazole; S16020

Networked: 5 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - NSC 659687: 5
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Carbazoles: 32
        NSC 659687: 5
  - 3-Ring Heterocyclic Compounds
    - Carbazoles: 32
      - NSC 659687: 5

Experts

1.	Barg, Ewa: 1 article (01/2022)
2.	Chabowska, Gabriela: 1 article (01/2022)
3.	Moreira, Helena: 1 article (01/2022)
4.	Tylińska, Beata: 1 article (01/2022)
5.	Aubert, Geneviève: 1 article (05/2003)
6.	Grill, Jacques: 1 article (05/2003)
7.	Kalifa, Chantal: 1 article (05/2003)
8.	Lucas, Catherine: 1 article (05/2003)
9.	Merlin, Jean-Louis: 1 article (05/2003)
10.	Morizet, Jackie: 1 article (05/2003)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2003 - "In conclusion, S16020 and doxorubicin showed significant antitumor activity in brain tumor xenografts treated at an advanced stage of tumor growth. " 05/01/2003 - "S16020 is a cytotoxic olivacine derivative that inhibits topoisomerase II. The aim of the study was to determine its antitumor activity in athymic mice bearing subcutaneous medulloblastoma (IGRM33, 34, 57) and glioblastoma (IGRG88, 93, 121) xenografts treated at an advanced stage of tumor growth in comparison with that of doxorubicin. " 02/03/1999 - "Among the inhibitors of the enzyme topoisomerase II (an important target for chemotherapeutic drugs) tested in the National Cancer Institute's In Vitro Antineoplastic Drug Screen, NSC 284682 (3'-hydroxydaunorubicin) and NSC 659687 [9-hydroxy-5,6-dimethyl-1-(N-[2(dimethylamino)ethyl]carbamoyl)-6H-pyrido -(4,3-b)carbazole] were the only compounds that were more cytotoxic to tumor cells harboring an activated ras oncogene than to tumor cells bearing wild-type ras alleles. "
2.	Pain (Aches) 03/01/2003 - "With S16020, there was a high incidence of severe non-haematological toxicities, including asthenia, oedema of the face, oedema and pain at the tumour sites and erythematous rash; consequently, both studies were stopped. "
3.	Medulloblastoma 05/01/2003 - "S16020 demonstrated a significant antitumor activity in two out of three medulloblastoma xenografts. " 05/01/2003 - "S16020 is a cytotoxic olivacine derivative that inhibits topoisomerase II. The aim of the study was to determine its antitumor activity in athymic mice bearing subcutaneous medulloblastoma (IGRM33, 34, 57) and glioblastoma (IGRG88, 93, 121) xenografts treated at an advanced stage of tumor growth in comparison with that of doxorubicin. "
4.	Head and Neck Neoplasms (Head and Neck Cancer) 03/01/2003 - "Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer." 03/01/2003 - "The purpose of this study was to carry out two randomised phase II trials of S16020, a new olivacine derivative, tested as a single agent in patients with recurrent head and neck cancer, using methotrexate as the control arm to validate the results. "
5.	Glioblastoma (Glioblastoma Multiforme) 05/01/2003 - "S16020 demonstrated a significant antitumor activity in the three glioblastoma xenografts evaluated. " 05/01/2003 - "S16020 is a cytotoxic olivacine derivative that inhibits topoisomerase II. The aim of the study was to determine its antitumor activity in athymic mice bearing subcutaneous medulloblastoma (IGRM33, 34, 57) and glioblastoma (IGRG88, 93, 121) xenografts treated at an advanced stage of tumor growth in comparison with that of doxorubicin. "

Related Drugs and Biologics

1.	olivacine
2.	Type II DNA Topoisomerases (Topoisomerase II)
3.	Methotrexate (Mexate)
4.	Doxorubicin (Adriamycin)
5.	Topoisomerase II Inhibitors
6.	Enzymes
7.	Antineoplastic Agents (Antineoplastics)
8.	NSC 284682
9.	carbazole